NOS1AP基因rs12742393位点多态性对瑞格列奈治疗我国汉族2型糖尿病患者疗效的影响(5)
[11] REAVEN GM. What do we learn from measurements of HOMA-IR？[J]. Diabetologia， 2013， 56(8)：1867-1868.
[12] WRATTEN NS， MEMOLI H， HUANG Y， et al. Identification of a schizophrenia associated functional noncoding variant in NOS1AP[J]. Am J Psychiatry， 2009， 166(4)：434-441.
[13] QIN W， ZHANG R， HU C， et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese[J]. Acta Pharmacol Sin， 2010， 31(4)： 450-454.
, http://www.100md.com
[14] BECKER ML， AARNOUDSE AJ， NEWTON-CHEH C， et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea[J]. Pharmacogenet Genomics，2008，18(7)：591-597.
[15] CHO HJ， LEE SY， KIM YG， et al. Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population[J]. Clin Chim Acta， 2011， 412(19/20)：1831-1834.
, http://www.100md.com [16] PAHWA S， ALAM K， CROWE A， et al. Pretreatment with rifampicin and tyrosine kinase inhibitor dasatinib potentiates the inhibitory effects toward OATP1B1-and OATP1B3-mediated transport[J]. J Pharm Sci， 2017，106(8)：2123-2135.
[17] TOMALIK-SCHARTE D， FUHR U， HELLMICH M， et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide[J]. Drug Metab Dispos， 2011，39(5)：927-932.
[18] KALLIOKOSKI A，NEUVONEN M，NEUVONEN PJ，et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol，2008，48(3)：311- 321.
, http://www.100md.com
[19] HSIEH KP， LIN YY， CHENG CL， et al. Novel mutations of CYP3A4 in Chinese[J]. Drug Metab Dispos， 2001，29(3)：268-273.
[20] TURINI P， THALMANN S， JAYET PY， et al. Insulin resistance in mice lacking neuronal nitric oxide synthase is related to an alpha-adrenergic mechanism[J]. Swiss Med Wkly，2007，137(49/50)：700-704.
[21] RIZZO MA， PISTON DW. Regulation of beta cell glucokinase by S-nitrosylation and association with nitric oxide synthase[J]. J Cell Biol， 2003， 161(2)： 243-248.
, http://www.100md.com
[22] SHANKAR RR， WU Y， SHEN HQ， et al. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance[J]. Diabetes，2000，49(5)：684-687.
[23] LIPSKA KJ， KRUMHOLZ HM. Is hemoglobin A1c the right outcome for studies of diabetes？[J]. JAMA， 2017， 317(10)：1017-1018.
(收稿日期：2017-07-09 修回日期：2018-03-16)
(編辑：张元媛), 百拇医药(王涛 鲁茜 高杏 李伟 吕冬梅)
[12] WRATTEN NS， MEMOLI H， HUANG Y， et al. Identification of a schizophrenia associated functional noncoding variant in NOS1AP[J]. Am J Psychiatry， 2009， 166(4)：434-441.
[13] QIN W， ZHANG R， HU C， et al. A variation in NOS1AP gene is associated with repaglinide efficacy on insulin resistance in type 2 diabetes of Chinese[J]. Acta Pharmacol Sin， 2010， 31(4)： 450-454.
, http://www.100md.com
[14] BECKER ML， AARNOUDSE AJ， NEWTON-CHEH C， et al. Common variation in the NOS1AP gene is associated with reduced glucose-lowering effect and with increased mortality in users of sulfonylurea[J]. Pharmacogenet Genomics，2008，18(7)：591-597.
[15] CHO HJ， LEE SY， KIM YG， et al. Effect of genetic polymorphisms on the pharmacokinetics and efficacy of glimepiride in a Korean population[J]. Clin Chim Acta， 2011， 412(19/20)：1831-1834.
, http://www.100md.com [16] PAHWA S， ALAM K， CROWE A， et al. Pretreatment with rifampicin and tyrosine kinase inhibitor dasatinib potentiates the inhibitory effects toward OATP1B1-and OATP1B3-mediated transport[J]. J Pharm Sci， 2017，106(8)：2123-2135.
[17] TOMALIK-SCHARTE D， FUHR U， HELLMICH M， et al. Effect of the CYP2C8 genotype on the pharmacokinetics and pharmacodynamics of repaglinide[J]. Drug Metab Dispos， 2011，39(5)：927-932.
[18] KALLIOKOSKI A，NEUVONEN M，NEUVONEN PJ，et al. Different effects of SLCO1B1 polymorphism on the pharmacokinetics and pharmacodynamics of repaglinide and nateglinide[J]. J Clin Pharmacol，2008，48(3)：311- 321.
, http://www.100md.com
[19] HSIEH KP， LIN YY， CHENG CL， et al. Novel mutations of CYP3A4 in Chinese[J]. Drug Metab Dispos， 2001，29(3)：268-273.
[20] TURINI P， THALMANN S， JAYET PY， et al. Insulin resistance in mice lacking neuronal nitric oxide synthase is related to an alpha-adrenergic mechanism[J]. Swiss Med Wkly，2007，137(49/50)：700-704.
[21] RIZZO MA， PISTON DW. Regulation of beta cell glucokinase by S-nitrosylation and association with nitric oxide synthase[J]. J Cell Biol， 2003， 161(2)： 243-248.
, http://www.100md.com
[22] SHANKAR RR， WU Y， SHEN HQ， et al. Mice with gene disruption of both endothelial and neuronal nitric oxide synthase exhibit insulin resistance[J]. Diabetes，2000，49(5)：684-687.
[23] LIPSKA KJ， KRUMHOLZ HM. Is hemoglobin A1c the right outcome for studies of diabetes？[J]. JAMA， 2017， 317(10)：1017-1018.
(收稿日期：2017-07-09 修回日期：2018-03-16)
(編辑：张元媛), 百拇医药(王涛 鲁茜 高杏 李伟 吕冬梅)